Syncom Healthcare Ltd
Syncom Healthcare together with its one wholly owned foreign subsidiary operates as an integrated international pharmaceutical organisation with businesses encompassing the entire value chain in the marketing, production (including job work) and distribution of pharmaceutical products.
- Market Cap ₹ 16.8 Cr.
- Current Price ₹ 4.20
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 2.62
- Dividend Yield 0.00 %
- ROCE -11.3 %
- ROE -17.7 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 365 to 148 days.
- Company's working capital requirements have reduced from 394 days to 86.3 days
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -27.3% over past five years.
- Company has a low return on equity of -9.22% over last 3 years.
- Contingent liabilities of Rs.7.57 Cr.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|---|
| 135 | 204 | 191 | 191 | 124 | 55 | 42 | |
| 130 | 196 | 194 | 189 | 123 | 57 | 47 | |
| Operating Profit | 5 | 8 | -3 | 2 | 1 | -2 | -5 |
| OPM % | 4% | 4% | -1% | 1% | 1% | -4% | -13% |
| 4 | 2 | 3 | 3 | 3 | -89 | -69 | |
| Interest | 2 | 4 | 4 | 5 | 3 | 3 | 0 |
| Depreciation | 2 | 2 | 4 | 5 | 5 | 5 | 4 |
| Profit before tax | 4 | 4 | -8 | -5 | -4 | -99 | -78 |
| Tax % | 20% | -0% | 42% | 29% | 19% | -8% | 0% |
| 3 | 4 | -4 | -4 | -3 | -107 | -78 | |
| EPS in Rs | 0.84 | 1.00 | -1.09 | -0.95 | -0.86 | -26.83 | -19.56 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -27% |
| 3 Years: | -40% |
| TTM: | -25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 64% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 18% |
| 3 Years: | 9% |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | -9% |
| Last Year: | -18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 40 | 40 | 40 | 40 | 40 | 40 | 40 |
| Reserves | 143 | 151 | 158 | 158 | 163 | 49 | -30 |
| 22 | 31 | 37 | 28 | 31 | 26 | 25 | |
| 28 | 48 | 27 | 9 | 9 | 16 | 26 | |
| Total Liabilities | 234 | 270 | 262 | 236 | 243 | 130 | 61 |
| 16 | 26 | 28 | 23 | 21 | 20 | 16 | |
| CWIP | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| 213 | 245 | 234 | 212 | 222 | 110 | 44 | |
| Total Assets | 234 | 270 | 262 | 236 | 243 | 130 | 61 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|---|
| -200 | -1 | 1 | -1 | -8 | 4 | 6 | |
| 6 | -4 | 5 | 6 | 9 | 5 | -1 | |
| 105 | 5 | 1 | -13 | -1 | -10 | -5 | |
| Net Cash Flow | -89 | 1 | 7 | -8 | 0 | -1 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 287 | 315 | 300 | 291 | 486 | 461 | 148 |
| Inventory Days | 221 | 40 | 26 | 29 | 48 | 105 | 144 |
| Days Payable | 88 | 89 | 40 | 14 | 27 | 127 | 322 |
| Cash Conversion Cycle | 420 | 266 | 286 | 307 | 507 | 439 | -30 |
| Working Capital Days | 464 | 307 | 321 | 342 | 559 | 536 | 86 |
| ROCE % | 4% | -1% | -0% | -0% | -3% | -11% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Public Announcement-Delisting
23 Sep 2021 - Announcement (the "Announcement") is being issued to the Exchanges in respect of Delisting of its Equity Shares in accordance with Resolution Plan approved by the …
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
16 Aug 2021 - Submission of Non-applicability of Regulation 74(5) of SEBI (Depositories and Participants), Regulations, 2018 for the quarter ended 30TH June, 2021
-
Statement Of Investor Complaints For The Quarter Ended June 2021
16 Aug 2021 - No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Aug 2021 - Copies of the un-audited Financial Results for the first quarter ended 30th June, 2021 published in the newspaper "The Free Press Journal- Mumbai" - English …
- Shareholding for the Period Ended June 30, 2021 14 Aug 2021
Annual reports
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse